ArticleObesity science & practice2020
Exercise plus caloric restriction lowers soluble RAGE in adults with chronic kidney disease.
Article in Obesity science & practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Aerobic Exercise Training Increases Circulating sRAGE in Adults With Type 2 Diabetes: Associations With Sheddase Regulation.Diabetes, obesity & metabolism · 2026Trial
- Metformin Blunts Vascular Insulin Sensitivity After Exercise Training in Adults at Risk for Metabolic Syndrome.The Journal of clinical endocrinology and metabolism · 2026Trial
- Aerobic exercise training attenuates cardiac inflammation and fibrosis in mice with type 2 diabetes and inhibits the advanced glycation end products pathway.Diabetology & metabolic syndrome · 2026Article
- Nonpharmacologic and Nonsurgical Weight Management Interventions for Patients With Advanced CKD: A Scoping Review of the Medical Literature.Kidney medicine · 2025Review
- Soluble receptors for advanced glycation endproducts are predictors of insulin sensitivity and affected by weight loss.Nutrition & diabetes · 2024Article
- The RAGE/DIAPH1 axis: mediator of obesity and proposed biomarker of human cardiometabolic disease.Cardiovascular research · 2024Review
- Exercise Restores Hypothalamic Health in Obesity by Reshaping the Inflammatory Network.Antioxidants (Basel, Switzerland) · 2023Review
- Time-restricted feeding's effect on overweight and obese patients with chronic kidney disease stages 3-4: A prospective non-randomized control pilot study.Frontiers in endocrinology · 2023Article
- A single bout of exercise improves vascular insulin sensitivity in adults with obesity.Obesity (Silver Spring, Md.) · 2021 · on this mapArticle
- NADH/NADBiomolecules · 2021Review
- Review
- Exercise plus caloric restriction lowers soluble RAGE in adults with chronic kidney disease.Obesity science & practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
introductionThe incidence of chronic kidney disease (CKD) has increased in recent years. CKD is associated with obesity, type 2 diabetes, and cardiovascular disease, although the mechanism remains unclear. Elevated soluble form of the receptor for advanced glycation end products ( RAGE) is related to proinflammatory signaling pathways that may promote diabetic nephropathy and vascular dysfunction. Because lifestyle modification reduces systematic inflammation in adults with obesity and hyperglycaemia, the hypothesis that exercise plus caloric restriction would lower soluble RAGE in adults with CKD was tested in this study.
methodsEight adults (n = 6 females; age: 56.3 ± 2.8 y; BMI: 43.7 ± 2.2 kg/m
resultsExercise reduced body weight, fasting glucose, and fetuin-A as well as increased VO
conclusionsExercise and caloric restriction are effective at lowering soluble RAGE in relation to glucose regulation in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.